Answers are grounded in this paper and cite their sources.
Autism spectrum disorder (ASD) has a heterogeneous genetic architecture in which risk-associated genes may participate in interconnected molecular pathways. We present an graph-explainable multi-view graph neural network (GEM-GNN) for prioritizing ASD-associated genes by integrating protein-protein interaction (PPI) and brain-specific co-expression networks with genomic features. The model uses two GraphSAGE branches to learn representations from the structural and functional network views, combines these representations through a feature bottleneck, and applies an adjusted focal-loss objective to address class imbalance. Permutation feature importance and neighborhood subgraph extraction are used to examine the genomic and network evidence underlying candidate rankings. In experiments covering 19,832 protein-coding genes, the manuscript reports an area under the precision-recall curve of 0.8008, an area under the receiver operating characteristic curve of 0.93, an F1 score of 0.74 and a precision at 100 of 76%. An ablation analysis reports an AUPRC of 0.80 for the bottleneck-fusion model, compared with 0.71 for the PPI-only model, 0.69 for the co-expression-only model and 0.75 for simple concatenation. The authors also report that 85 high-ranking candidates overlap with independent de novo mutation evidence and that candidate genes are enriched for RNA polymerase II-mediated transcriptional processes. These results suggest that combining structural and brain-specific functional networks may support ASD gene prioritization and pathway-level interpretation. The reported performance and biological findings require interpretation in light of the dataset construction, evaluation protocol and validation procedures described in the manuscript.
No takes yet. Share an insight, caveat, or question.
Rasheed et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: